Bioavailability of Cinnarizine in Dogs: Effect of SNEDDS Loading Level and Correlation with Cinnarizine Solubilization During in Vitro Lipolysis

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2013 Aug 17

PMID 23949249

Citations 11

Authors

Anne T Larsen

Pernilla Akesson

Anna Jureus

Lasse Saaby

Ragheb Abu-Rmaileh

Bertil Abrahamsson

Jesper Ostergaard

Anette Mullertz

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the effect of increasing the loading level of the poorly soluble drug cinnarizine in a self-nanoemulsifying drug delivery system (SNEDDS) both in vitro and in vivo.

Methods: A fixed dose of cinnarizine was administered orally to dogs in solution in different amounts of SNEDDS vehicle. Furthermore, the SNEDDSs were characterised using the dynamic in vitro lipolysis model.

Results: Statistical differences in bioavailability were not obtained between the different amounts of SNEDDS vehicle, in spite of differences in the tendency of cinnarizine to precipitate during in vitro lipolysis of the treatments. Use of the SNEDDS concept decreased the variation in cinnarizine exposure observed between dogs as compared to administering cinnarizine in an aqueous suspension.

Conclusions: Optimization of SNEDDSs towards keeping the drug compound in solution upon in vitro lipolysis of the SNEDDSs may not be as important as previously suggested.

Citing Articles

Application of a Novel Dissolution Medium with Lipids for In Vitro Simulation of the Postprandial Gastric Content.

Felicijan T, Rakose I, Prislan M, Locatelli I, Bogataj M, Trontelj J Pharmaceutics. 2024; 16(8).

PMID: 39204385 PMC: 11359312. DOI: 10.3390/pharmaceutics16081040.

Supersaturation and Solubilization upon In Vitro Digestion of Fenofibrate Type I Lipid Formulations: Effect of Droplet Size, Surfactant Concentration and Lipid Type.

Katev V, Tsibranska-Gyoreva S, Vinarov Z, Tcholakova S Pharmaceutics. 2021; 13(8).

PMID: 34452248 PMC: 8399075. DOI: 10.3390/pharmaceutics13081287.

Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery.

Buya A, Beloqui A, Memvanga P, Preat V Pharmaceutics. 2020; 12(12).

PMID: 33317067 PMC: 7764143. DOI: 10.3390/pharmaceutics12121194.

Suitability of Artificial Membranes in Lipolysis-Permeation Assays of Oral Lipid-Based Formulations.

Hedge O, Bergstrom C Pharm Res. 2020; 37(6):99.

PMID: 32435855 PMC: 7239831. DOI: 10.1007/s11095-020-02833-9.

Comparisons of in vitro Fick's first law, lipolysis, and in vivo rat models for oral absorption on BCS II drugs in SNEDDS.

Ye J, Wu H, Huang C, Lin W, Zhang C, Huang B Int J Nanomedicine. 2019; 14:5623-5636.

PMID: 31440045 PMC: 6664859. DOI: 10.2147/IJN.S203911.

References

Sassene P, Knopp M, Hesselkilde J, Koradia V, Larsen A, Rades T . Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. J Pharm Sci. 2010; 99(12):4982-91. DOI: 10.1002/jps.22226. View

Constantinides P, Wasan K . Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 2006; 96(2):235-48. DOI: 10.1002/jps.20780. View

Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004; 5(1):6-13. DOI: 10.1038/sj.tpj.6500285. View

Kleberg K, Jacobsen F, Fatouros D, Mullertz A . Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. J Pharm Sci. 2010; 99(8):3522-32. DOI: 10.1002/jps.22122. View

Larsen A, Holm R, Pedersen M, Mullertz A . Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm Res. 2008; 25(12):2769-77. DOI: 10.1007/s11095-008-9641-0. View

Paulson S, Engel L, Reitz B, Bolten S, Burton E, Maziasz T . Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos. 1999; 27(10):1133-42. View

Han S, Yao T, Zhang X, Gan L, Zhu C, Yu H . Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Int J Pharm. 2009; 379(1):18-24. DOI: 10.1016/j.ijpharm.2009.06.001. View

Kossena G, Charman W, Boyd B, Porter C . A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs. J Control Release. 2004; 99(2):217-29. DOI: 10.1016/j.jconrel.2004.06.013. View

Larsen A, Ohlsson A, Polentarutti B, Barker R, Phillips A, Abu-Rmaileh R . Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci. 2012; 48(1-2):339-50. DOI: 10.1016/j.ejps.2012.11.004. View

10.

Thomas N, Holm R, Garmer M, Karlsson J, Mullertz A, Rades T . Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J. 2012; 15(1):219-27. PMC: 3535117. DOI: 10.1208/s12248-012-9433-7. View

11.

Artursson P, Karlsson J . Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991; 175(3):880-5. DOI: 10.1016/0006-291x(91)91647-u. View

12.

Marasini N, Yan Y, Poudel B, Choi H, Yong C, Kim J . Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function. J Pharm Sci. 2012; 101(12):4584-96. DOI: 10.1002/jps.23333. View

13.

Martignoni M, Groothuis G, de Kanter R . Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006; 2(6):875-94. DOI: 10.1517/17425255.2.6.875. View

14.

Rautio J, Humphreys J, Webster L, Balakrishnan A, Keogh J, Kunta J . In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006; 34(5):786-92. DOI: 10.1124/dmd.105.008615. View

15.

Jarvinen T, Jarvinen K, Schwarting N, Stella V . beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J Pharm Sci. 1995; 84(3):295-9. DOI: 10.1002/jps.2600840306. View

16.

Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G . Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm. 2004; 278(1):119-31. DOI: 10.1016/j.ijpharm.2004.03.001. View

17.

Larsen A, Ogbonna A, Abu-Rmaileh R, Abrahamsson B, Ostergaard J, Mullertz A . SNEDDS Containing Poorly Water Soluble Cinnarizine; Development and in Vitro Characterization of Dispersion, Digestion and Solubilization. Pharmaceutics. 2013; 4(4):641-65. PMC: 3834928. DOI: 10.3390/pharmaceutics4040641. View

18.

Grove M, Pedersen G, Nielsen J, Mullertz A . Bioavailability of seocalcitol I: Relating solubility in biorelevant media with oral bioavailability in rats--effect of medium and long chain triglycerides. J Pharm Sci. 2005; 94(8):1830-8. DOI: 10.1002/jps.20403. View

19.

Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R . Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2001; 26(3):193-200. DOI: 10.1007/BF03190396. View

20.

Narimatsu S, Kariya S, Isozaki S, Ohmori S, Kitada M, Hosokawa S . Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem Biophys Res Commun. 1993; 193(3):1262-8. DOI: 10.1006/bbrc.1993.1761. View